Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

BACKGROUND: There has been uncertainty regarding the benefit of glycemic control with antidiabetic agents in prevention of diabetic macrovascular disease. Further development of novel antidiabetic agents is essential for overcoming the burden of diabetic macrovascular disease. The renal sodium gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Bowen, Koibuchi, Nobutaka, Hasegawa, Yu, Sueta, Daisuke, Toyama, Kensuke, Uekawa, Ken, Ma, MingJie, Nakagawa, Takashi, Kusaka, Hiroaki, Kim-Mitsuyama, Shokei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219031/
https://www.ncbi.nlm.nih.gov/pubmed/25344694
http://dx.doi.org/10.1186/s12933-014-0148-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219031/
https://www.ncbi.nlm.nih.gov/pubmed/25344694
http://dx.doi.org/10.1186/s12933-014-0148-1

Ejemplares similares